SHINE receives Dutch approval to improve access to nuclear medicine
– SHINE receives Dutch approval for a project to improve patient access to promising new nuclear medicine
Approval of SHINE Europe grant proposal by Dutch government, first step towards terbium production
VEENDAM, Netherlands and BARCELONASpain, October 18, 2022 /PRNewswire/ — EANM stand #63 — SHINE Technologies, a next-generation fusion technology company, and SHINE Europe today announced that the Dutch government has approved a significant grant proposal to develop a plan to produce different isotopes of terbium for use in nuclear medicine.
Within this project, SHINE Europe, together with the University Medical Center Groningen (UMCG) and the Delft University of Technology (TU Delft), aims to develop and implement all the necessary technologies and facilities to ensure the entire supply chain of terbium nuclear medicine. This will also include enhanced cooperation with partners in the European Union. “Previous collaborations with UMCG and TU Delft have been very fruitful,” said Harry Bürlage, General Manager of SHINE Europe. “Therefore, we look to our collaboration on the project with great confidence.”
Research shows that terbium isotopes are a potentially effective method for diagnosing and treating cancer and other diseases. But on Lack of basic raw materials and complex processing technology are among the current barriers to terbium production. These obstacles can be solved with SHINE’s innovative production methods. They enable SHINE to have a vertically integrated supply chain, from the production of raw materials to the purification of cGMP products.
SHINE, a world leader in new high-tech ways to manufacture drugs, is currently producing lutetium-177 c Janesville, Wisconsin (USA). It is building the world’s largest fully dedicated medical isotope production facility at its campus in Janesville, which will add the ability to produce molybdenum-99, a diagnostic drug used in millions of procedures to detect heart disease and cancer. The facility is expected to become operational in 2023 and will be able to produce a fission-based radioisotope package as well as key neutron capture-based isotopes. GLITTER Europe is planning a similar manufacturing facility in Veendam, the Netherlands, to come online within the next five years.
“The development of a new terbium-based drug delivery system will be another important milestone in giving patients access to promising new therapies to support their ongoing fight against cancer,” said Harry Bourlage, General Manager of SHINE Europe. “We thank the Dutch government for their support in our terbium efforts and look forward to similar support from the European Commission.” The grant proposal is subject to final approval by the European Commission.
About GLITTER
SHINE is a next generation nuclear technology company deploying advanced fusion technologies to create a scalable path to fusion power. Based in South Wisconsinlocated in Janesville and with a future site under development in Europe, SHINE is deploying its safe, cost-effective and environmentally friendly technology in a phased approach. SHINE systems are used for industrial imaging of components in the aerospace, defense, transportation, energy and other industries. SHINE’s proprietary isotope production processes create carrier-free molybdenum-99 and lutetium-177, which are used in tens of thousands of daily procedures to diagnose and treat heart disease and cancer. More information at https://www.shinefusion.com/shine-europe-home/ or at https://www.linkedin.com/company/80677859
Logo – https://mma.prnewswire.com/media/1797570/SHINE_Logo.jpg
See original content: https://www.prnewswire.com/news-releases/shine-gets-dutch-approval-for-improving-access-to-nuclear-medicine-301652585.html
